GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond)

Slides:

Advertisements

Similar presentations

Dose-escalation patient response.

Advertisements

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Volume 70, Issue 8, Pages (October 2006)

Nat. Rev. Nephrol. doi: /nrneph

Current Therapy for Type II Diabetes

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Figure 5 Risk factor control in the intensive treatment group

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Outcomes with dual RAAS inhibition with an ACE inhibitor and ARB vs standard therapy in patients on hemodialysis with CHF standard therapy in patients.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

X-bar and S control charts of LOS

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Chronic PDGFRα activation reduces sensitivity of PDGFRα-positive GBM cells to translational inhibitor–induced suppression on cell viability. Chronic PDGFRα.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.

Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Plasma levels of GLP-1 are increased in patients with critical illness and correlate with disease severity. Plasma levels of GLP-1 are increased in patients.

A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.

Annual change in muscle strength of ankle plantar flexion (A) and of ankle dorsal flexion (B) for the three subgroups of diabetic patients and their matched.

Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

The prevalence of type 2 diabetes for R1420H carriers and noncarriers in relation to BMI. Diabetes prevalence is shown in individuals stratified by their.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Waveform analysis at the popliteal artery in 176 diabetic patients with normal ABI (non-PAD). Waveform analysis at the popliteal artery in 176 diabetic.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Noncontrast computed tomography of patient C. B

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Plots of average estimated and measured GFR vs

Forest plots of pooled studies ultrasound-guided lavage with a corticosteroid injection to shockwave therapy for change in pain in patient with chronic.

Patient disposition and study protocol.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

A: Probability of retinopathy-free survival.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Prevalence of prescribing of different anti-diabetic medications among all patients with type 2 diabetes on treatment. *Other=Sum of prevalence of Acarbose,

Pathway to initial antihypertensive therapy in patients with diabetes

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Example of severe periodontitis in an African-American patient with uncontrolled diabetes (A1C > 9.0%) who has not responded to initial periodontal therapy.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Presentation transcript:

GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond) ACE inhibitor therapy and two-kidney patients with (open triangle) and without (closed triangle) ACE inhibitor therapy. GBM width (A), Vv(Mes/glom) (B), Vv(MM/glom) (C), Vv(MC/glom) (D), and Vv(MM/mes) (E) in one-kidney patients with (open diamond) and without (closed diamond) ACE inhibitor therapy and two-kidney patients with (open triangle) and without (closed triangle) ACE inhibitor therapy. The shaded area is 5 and 95% CI for the control subjects (A) and mean ± 2 SD for the control subjects (B–E). Shirley Chang et al. Diabetes 2008;57:1707-1711 ©2008 by American Diabetes Association